Sugi Predict

Sugi Predict / Compounds / SCHEMBL19748091

SCHEMBL19748091

SCHEMBL19748091

CCS(=O)(=O)Nc1cc(Br)cnc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSIP1 O75475 1/20 0.44
▸ ALOX5AP P20292 2/20 0.37
▸ FEN1 P39748 2/20 0.37
▸ LMNA P02545 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ BRD4 O60885 1/20 0.35
▸ PLA2G1B P04054 1/20 0.35
▸ ATG4B Q9Y4P1 1/20 0.35
▸ JAK2 O60674 3/20 0.35
▸ JAK1 P23458 3/20 0.35
▸ TYK2 P29597 3/20 0.35
▸ JAK3 P52333 3/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MRGPRX1 Q96LB2 3/20 0.34
▸ BRAF P15056 1/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856790 0.83 SLC22A12 (0.44) ALOX5APFEN1PLA2G1BATG4BNPC1
SCHEMBL18595670 0.82 PSIP1 (0.45) PSIP1ALOX5APFEN1LMNAHPGD
SCHEMBL3114091 0.81 PIK3CG (0.43) PSIP1LMNAHPGDHSD17B10BRD4
SCHEMBL17996189 0.79 PSIP1 (0.42) PSIP1ALOX5APFEN1LMNAHPGD
SCHEMBL17969358 0.78 HPGD (0.44) LMNAHPGDHSD17B10ALDH1A1BRAF
SCHEMBL2067182 0.76 GABRA1 (0.36) LMNAJAK2NPC1ALDH1A1KMT2A
SCHEMBL29104520 0.76 PTGS1 (0.36) PSIP1LMNAHPGDHSD17B10BRD4
SCHEMBL22230597 0.74 SLC40A1 (0.49) ALDH1A1MEN1KMT2A
SCHEMBL3513683 0.73 HTT (0.34) LMNAHSD17B10JAK2NPC1ALDH1A1
SCHEMBL23014434 0.71 NPC1 (0.37) ALOX5APFEN1HSD17B10PLA2G1BATG4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-07-09 — — US disclosed
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-08-11 — — US disclosed
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 — — US disclosed
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 — — US disclosed
US-20200102315-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-04-02 — — US disclosed
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2019-11-19 — — US disclosed
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2019-11-19 — — US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 — — US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 — — US disclosed
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors INCYTE CORPORATION (US) 2018-11-27 — — US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 — — US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 — — US disclosed
WO-2017223414-A1 HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS INCYTE CORPORATION (US) 2017-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CA PSIP1 2385/4885ALOX5AP 2939/4885FEN1 1812/4885
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3R5 PSIP1 3073/4885ALOX5AP 3317/4885FEN1 2266/4885
US-20200102315-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PSIP1 4390/4885ALOX5AP 2472/4885FEN1 2794/4885
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors PIK3CA, PIK3CG, PIK3CD PSIP1 2290/4885ALOX5AP 3337/4885FEN1 1566/4885
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors PIK3R5, PIK3CD, PIK3CA PSIP1 3212/4885ALOX5AP 3045/4885FEN1 2882/4885
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PSIP1 4390/4885ALOX5AP 2472/4885FEN1 2794/4885
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PSIP1 4390/4885ALOX5AP 2472/4885FEN1 2794/4885
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PSIP1 4390/4885ALOX5AP 2472/4885FEN1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.